805 related articles for article (PubMed ID: 17188780)
1. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis.
Warshaw EM; Wohlhuter RJ; Liu A; Zeller SA; Wenner RA; Bowers S; Schultz JC; Katz HI; McCormick CL; Parneix-Spake A
J Am Acad Dermatol; 2007 Aug; 57(2):257-64. PubMed ID: 17188780
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
3. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
Gribetz C; Ling M; Lebwohl M; Pariser D; Draelos Z; Gottlieb AB; Zaias N; Chen DM; Parneix-Spake A; Hultsch T; Menter A
J Am Acad Dermatol; 2004 Nov; 51(5):731-8. PubMed ID: 15523351
[TBL] [Abstract][Full Text] [Related]
4. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
Hoeger PH; Lee KH; Jautova J; Wohlrab J; Guettner A; Mizutani G; Hultsch T
Br J Dermatol; 2009 Feb; 160(2):415-22. PubMed ID: 19067708
[TBL] [Abstract][Full Text] [Related]
5. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study.
Cicek D; Kandi B; Bakar S; Turgut D
J Dermatolog Treat; 2009; 20(6):344-9. PubMed ID: 19954391
[TBL] [Abstract][Full Text] [Related]
6. Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face and neck.
Mensing CO; Mensing CH; Mensing H
Int J Dermatol; 2008 Sep; 47(9):960-4. PubMed ID: 18937664
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
8. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study.
Seckin D; Gurbuz O; Akin O
J Eur Acad Dermatol Venereol; 2007 Mar; 21(3):345-50. PubMed ID: 17309456
[TBL] [Abstract][Full Text] [Related]
9. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study.
Barikbin B; Givrad S; Yousefi M; Eskandari F
Clin Exp Dermatol; 2009 Oct; 34(7):776-80. PubMed ID: 19456797
[TBL] [Abstract][Full Text] [Related]
10. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study.
Ozden MG; Tekin NS; Ilter N; Ankarali H
Am J Clin Dermatol; 2010; 11(1):51-4. PubMed ID: 20000875
[TBL] [Abstract][Full Text] [Related]
11. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption.
Chu CY
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):484-90. PubMed ID: 17373975
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis.
Schwarz T; Kreiselmaier I; Bieber T; Thaci D; Simon JC; Meurer M; Werfel T; Zuberbier T; Luger TA; Wollenberg A; Bräutigam M
J Am Acad Dermatol; 2008 Jul; 59(1):34-40. PubMed ID: 18462835
[TBL] [Abstract][Full Text] [Related]
13. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial.
Gollnick H; Kaufmann R; Stough D; Heikkila H; Andriano K; Grinienko A; Jimenez P;
Br J Dermatol; 2008 May; 158(5):1083-93. PubMed ID: 18341665
[TBL] [Abstract][Full Text] [Related]
14. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis.
Koc E; Arca E; Kose O; Akar A
J Dermatolog Treat; 2009; 20(1):4-9. PubMed ID: 18677657
[TBL] [Abstract][Full Text] [Related]
15. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Rigopoulos D; Ioannides D; Kalogeromitros D; Gregoriou S; Katsambas A
Br J Dermatol; 2004 Nov; 151(5):1071-5. PubMed ID: 15541087
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants.
Ho VC; Gupta A; Kaufmann R; Todd G; Vanaclocha F; Takaoka R; Fölster-Holst R; Potter P; Marshall K; Thurston M; Bush C; Cherill R
J Pediatr; 2003 Feb; 142(2):155-62. PubMed ID: 12584537
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis.
Fleischer AB; Abramovits W; Breneman D; Jaracz E;
J Dermatolog Treat; 2007; 18(3):151-7. PubMed ID: 17538803
[TBL] [Abstract][Full Text] [Related]
18. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream.
Abramovits W; Fleischer AB; Jaracz E; Breneman D
J Drugs Dermatol; 2008 Dec; 7(12):1153-8. PubMed ID: 19137769
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
[TBL] [Abstract][Full Text] [Related]
20. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial.
Firooz A; Solhpour A; Gorouhi F; Daneshpazhooh M; Balighi K; Farsinejad K; Rashighi-Firoozabadi M; Dowlati Y
Arch Dermatol; 2006 Aug; 142(8):1066-7. PubMed ID: 16924062
[No Abstract] [Full Text] [Related]
[Next] [New Search]
